Peregrine Pharma (PPHM) Misses Q1 EPS by 1c

Peregrine Pharma (NASDAQ: PPHM) reported Q1 EPS of ($0.05), $0.01 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $5.61 million versus the consensus estimate of $13.09 million.

GUIDANCE:

Peregrine Pharma sees Q2 2017 revenue of $20 million, versus the consensus of $12.5 million.

• Company Reaffirms Revenue Projection of $50 - $55 Million for Full FY 2017 with Growing Backlog of Business

For earnings history and earnings-related data on Peregrine Pharma (PPHM) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Micron Technology (MU) Tops Q4 EPS by $2.26, Offers Guidance
• Carnival Corp. (CCL) Tops Q3 EPS by 8c